Literature DB >> 9323945

Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost.

M A Johnstone1.   

Abstract

PURPOSE: To describe hypertrichosis and increased pigmentation of eyelashes associated with topical latanoprost usage.
METHODS: Patients using unilateral topical latanoprost for glaucoma were examined for evidence of hypertrichosis and pigmentation of eyelashes and adjacent hair in the latanoprost-treated eye compared with the nontreated control eye.
RESULTS: In 43 patients receiving unilateral topical latanoprost, hypertrichosis involved ipsilateral terminal eyelashes and regional intermediate hairs of the upper and lower eyelid as well as vellus hair of the lower eyelid skin. Differences in hair appearance between the latanoprost-treated eye and the nontreated control eye included increased number, length, thickness, curvature, and pigmentation.
CONCLUSIONS: Latanoprost-treated eyes develop hypertrichosis and increased pigmentation in the region of treatment. Patients may benefit from being made aware of this side effect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9323945     DOI: 10.1016/s0002-9394(14)70870-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  31 in total

Review 1.  Efficacy and adverse effects of medications used in the treatment of glaucoma.

Authors:  C B Camras; C B Toris; R R Tamesis
Journal:  Drugs Aging       Date:  1999-11       Impact factor: 3.923

Review 2.  Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? The controversy.

Authors:  I Goldberg
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

Review 3.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

4.  2-MeS-beta,gamma-CCl2-ATP is a potent agent for reducing intraocular pressure.

Authors:  Shay Eliahu; Alba Martín-Gil; María Jesús Perez de Lara; Jesús Pintor; Jean Camden; Gary A Weisman; Joanna Lecka; Jean Sévigny; Bilha Fischer
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

Review 5.  Evolving paradigms in the medical treatment of glaucoma.

Authors:  John S Cohen; Anup K Khatana; Linda J Greff
Journal:  Int Ophthalmol       Date:  2006-03-07       Impact factor: 2.031

Review 6.  Using human experience to identify drug repurposing opportunities: theory and practice.

Authors:  D Cavalla
Journal:  Br J Clin Pharmacol       Date:  2019-02-03       Impact factor: 4.335

7.  Incidence of iris colour change in latanoprost treated eyes.

Authors:  M A Teus; E Arranz-Márquez; P Lucea-Suescun
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

8.  Bimatoprost in the treatment of eyelash hypotrichosis.

Authors:  Simon K Law
Journal:  Clin Ophthalmol       Date:  2010-04-26

9.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

10.  Recent advances in pharmacotherapy of glaucoma.

Authors:  S K Gupta; Galpalli Niranjan D; S S Agrawal; Sushma Srivastava; Rohit Saxena
Journal:  Indian J Pharmacol       Date:  2008-10       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.